Kura Oncology/$KURA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kura Oncology
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Ticker
$KURA
Sector
Primary listing
Employees
192
Headquarters
Website
Kura Oncology Metrics
BasicAdvanced
$929M
-
-$2.48
0.23
-
Price and volume
Market cap
$929M
Beta
0.23
52-week high
$17.44
52-week low
$5.41
Average daily volume
2M
Financial strength
Current ratio
5.117
Quick ratio
4.828
Long term debt to equity
5.649
Total debt to equity
8.026
Interest coverage (TTM)
-152.85%
Profitability
EBITDA (TTM)
-238.985
Gross margin (TTM)
-47.44%
Net profit margin (TTM)
-208.48%
Operating margin (TTM)
-230.53%
Effective tax rate (TTM)
-1.05%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-26.57%
Return on equity (TTM)
-65.10%
Valuation
Price to revenue (TTM)
8.978
Price to book
3.83
Price to tangible book (TTM)
3.83
Price to free cash flow (TTM)
11.237
Free cash flow yield (TTM)
8.90%
Free cash flow per share (TTM)
0.95
Growth
Earnings per share change (TTM)
5.11%
3-year earnings per share growth (CAGR)
6.81%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Bulls say / Bears say
The FDA has accepted the New Drug Application for ziftomenib and granted it Priority Review, setting a PDUFA action date of November 30, 2025. This marks a significant regulatory milestone as it is the first potential approval of a menin inhibitor (GlobeNewswire).
Kura has finished building its U.S. field sales force and has progressed with pre-launch commercial preparations, including medical affairs, market access, patient support, and engagement with stakeholders, placing the company in a strong position for swift market entry if approval is granted (GlobeNewswire).
In the KOMET-001 pivotal trial, ziftomenib achieved a complete remission plus CRh rate of 23% in a heavily pretreated group of patients with relapsed/refractory NPM1-mutant AML. The data, presented at the 2025 ASCO Annual Meeting, indicate the drug's significant clinical efficacy (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Kura Oncology News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kura Oncology stock?
Kura Oncology (KURA) has a market cap of $929M as of November 13, 2025.
What is the P/E ratio for Kura Oncology stock?
The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of November 13, 2025.
Does Kura Oncology stock pay dividends?
No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of November 13, 2025.
When is the next Kura Oncology dividend payment date?
Kura Oncology (KURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kura Oncology?
Kura Oncology (KURA) has a beta rating of 0.23. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.